<DOC>
	<DOCNO>NCT00921570</DOCNO>
	<brief_summary>Diabetic nephropathy ( DN ) important complication diabetes mellitus ( DM ) common cause end-stage renal disease ( ESRD ) . Diabetic nephropathy clinical syndrome characterize persistent albuminuria ( &gt; 300 mg/d &gt; 200 mcg/min ) confirm least 2 occasion 3 6 month apart , relentless decline glomerular filtration rate ( GFR ) , elevate arterial blood pressure . In addition renal hemodynamic alteration , patient overt diabetic nephropathy ( dipstick-positive proteinuria decrease GFR ) generally develop systemic hypertension . Hypertension adverse factor progressive renal disease seem especially diabetic nephropathy . The deleterious effect hypertension likely directed vasculature microvasculature . Use angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin receptor blocker ( ARBs ) , strict glycemic control use antilipidemic drug may improve progression DN . TNF-like weak inducer apoptosis ( TWEAK , TNFSF12 ) member TNF superfamily structurally related cytokine . The human TWEAK gene encode 249-amino acid type II transmembrane glycoprotein ( 30 kD ) . TWEAK may express full-length , membrane-bound protein 156-amino acid , 18-kD soluble protein , ( sTWEAK ) result proteolysis TWEAK . TWEAK gene express many tissue , include brain , kidney , heart , arterial wall , monocytes macrophage . Reduced soluble TNF-like weak inducer apoptosis ( sTWEAK ) plasma level report patient subclinical atherosclerosis chronic kidney disease ( CKD ) . Long pentraxin 3 ( PTX3 ) multimeric inflammatory mediator . Increased serum PTX3 level report among end-stage renal disease patient . Moreover , PTX3 suggest represent novel mortality risk factor , elevate PTX3 level show accompany increase albuminuria among patient chronic kidney disease ( CKD ) . There data effect Renin angiotensin system blockage ( RAS ) , calcium channel blocker combine drug TWEAK PTX3 level diabetic proteinuric patient hypertension . The aim study find whether beneficial effect RAS blockage , calcium channel blocker combine drug diabetic hypertensive proteinuric patient relation alteration TWEAK PTX3 level . The investigator search effect angiotensin II ( AII ) receptor blocker ( Valsartan 160 mg ) , calcium channel blocker ( Amlodipine 10 mg ) AII receptor blocker plus calcium channel blocker ( Valsartan 160 mg + Amlodipine 10 mg ) clinical laboratory parameter diabetic hypertensive proteinuric patient .</brief_summary>
	<brief_title>The Effects Renin Angiotensin System Blockage ( RAS ) , Calcium Channel Blocker Combined Drugs TWEAK , PTX3 FMD Levels Diabetic Proteinuric Patients With Hypertension</brief_title>
	<detailed_description>The patient non-obese ( BMI &lt; 30kg/m2 ) , non dyslipidemic ( total cholesterol &lt; 200mg/dl , Triglyceride &lt; 150mg/dl ) , free cardiovascular event ( negative medical history , negative ECG finding ) investigate enrollment . CKD stage 1 patient old 18 year age willing participate study screen . From 375 patient establish type 2 diabetes mellitus+hypertension , 174 proteinuria and/or hypertension ( 24 h protein excretion 1-2 g/day , systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥ 90 mmHg , respectively ) . All case first referral time study treatment . Patients history coronary artery disease , smoker take statin renin-angiotensin blocker exclude effect factor endothelial dysfunction . Of 174 screen patient 107 meet study criterion include study . The duration proteinuria diabetic nephropathy initial diagnosis know . The exclusion criterion follow : A ) Nephrotic syndrome , B ) coronary heart disease ( patient ischemic ST-T alteration voltage criterion LVH electrocardiogram , history revascularization myocardial infarction ) , C ) elevate liver enzyme ( AST ALT level ≥ 40U/L ) D ) renal failure ( serum creatinine level &gt; 1.3 mg/dl ) . In order evaluate effect RAS blockade plasma TWEAK PTX3 concentration , patient proteinuria give AII receptor blocker ( Valsartan 160 mg ) , calcium channel blocker ( Amlodipine 10 mg ) combine drug ( Valsartan 160 mg + Amlodipine 10 mg ) 12 week . The effect RAS blockade insulin sensitivity proteinuria also investigate . After intervention period , blood sample obtain assay plasma TWEAK PTX3 concentration , HbA1c , insulin resistance score ( HOMA-IR ) . Urine sample also collect 24-hour period determine degree proteinuria .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>CKD stage 1 patient Older 18 year age Type 2 Diabetic patient Proteinuria Hypertension History coronary artery disease Smokers Taking statins reninangiotensin blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>TWEAK</keyword>
	<keyword>FMD</keyword>
	<keyword>PTX3</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Renin Angiotensin System</keyword>
</DOC>